Abstracts of the 27th International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, 27-30 March 2007

Overview

Journal Crit Care

Specialty Critical Care

Date 2007 May 12

PMID 17493246

Citations 1

Affiliations

Soon will be listed here.

Citing Articles

Capillary Leak Syndrome Following Snakebite Envenomation.

Udayabhaskaran V, Arun Thomas E, Shaji B Indian J Crit Care Med. 2017; 21(10):698-702.

PMID: 29142382 PMC: 5672676. DOI: 10.4103/ijccm.IJCCM_41_17.

References

Angus D, Lidicker J, Clermont G, Carcillo J, Pinsky M . Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29(7):1303-10. DOI: 10.1097/00003246-200107000-00002. View

Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B . Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2002; 345(19):1368-77. DOI: 10.1056/NEJMoa010307. View

Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A . Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 2002; 28(2):108-21. DOI: 10.1007/s00134-001-1143-z. View

Martin G, Mannino D, Eaton S, Moss M . The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003; 348(16):1546-54. DOI: 10.1056/NEJMoa022139. View

Dellinger R, Carlet J, Masur H, Gerlach H, Calandra T, Cohen J . Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004; 32(3):858-73. DOI: 10.1097/01.ccm.0000117317.18092.e4. View

Nick J, Coldren C, Geraci M, Poch K, Fouty B, OBrien J . Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood. 2004; 104(13):3878-85. DOI: 10.1182/blood-2004-06-2140. View

Feistritzer C, Riewald M . Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. 2005; 105(8):3178-84. DOI: 10.1182/blood-2004-10-3985. View

Claessens Y, Dhainaut J . Diagnosis and treatment of severe sepsis. Crit Care. 2008; 11 Suppl 5:S2. PMC: 2230613. DOI: 10.1186/cc6153. View

Levi M, van der Poll T . Recombinant human activated protein C: current insights into its mechanism of action. Crit Care. 2008; 11 Suppl 5:S3. PMC: 2230607. DOI: 10.1186/cc6154. View

10.

Vangerow B, Shorr A, Wyncoll D, Janes J, Nelson D, Reinhart K . The protein C pathway: implications for the design of the RESPOND study. Crit Care. 2008; 11 Suppl 5:S4. PMC: 2230608. DOI: 10.1186/cc6155. View

11.

Laterre P . Clinical trials in severe sepsis with drotrecogin alfa (activated). Crit Care. 2008; 11 Suppl 5:S5. PMC: 2230609. DOI: 10.1186/cc6156. View

12.

Fumagalli R, Mignini M . The safety profile of drotrecogin alfa (activated). Crit Care. 2008; 11 Suppl 5:S6. PMC: 2230610. DOI: 10.1186/cc6157. View

13.

Camporota L, Wyncoll D . Practical aspects of treatment with drotrecogin alfa (activated). Crit Care. 2008; 11 Suppl 5:S7. PMC: 2230611. DOI: 10.1186/cc6158. View